Evaluation of serum cathepsin B and D in relation to clinicopathological staging of colorectal cancer

Table 1 Activity of cathepsin B and D in serum of patients with colorectal carcinoma

	Healthy people	Control serum	66.9 ± 2.8
	(n = 20)
Cathepsin B	Colorectal patients	Before operation1	7.9 ± 8.51b
nmoL pNA/mL	(n = 63)	(serum sample a)
		After operation	21.0 ± 8.7f
		(serum sample b)
	Healthy people	Control serum	30.2 ± 2.2
	(n = 20)
Cathepsin D	Colorectal patients	Before operation	58.7 ± 24.22d
nmoL Tyr/mL	(n = 63)	(serum sample a)
		After operation	49.9 ± 16.9h
		(serum sample b)

Statistical differences:

¹P = 0.031 -comparison between cathepsin B serum samples a and b.

²P = 0.09 -comparison between cathepsin D serum samples a and b.

^bP < 0.00001,

^dP < 0.00001,

^hP < 0.00001,

^fP < 0.00001 vs control serum.